Endologix has announced the appointment of Matthew Thompson as president and chief executive officer. Thompson will also join Endologix’s board of directors. Richard Mott, who previously held the CEO position on an interim basis, will return to his role as executive chairman of the board of directors.
Thompson has been serving as Endologix’s chief medical officer since 2016, and, in that capacity, had oversight of the company’s business development, medical affairs, regulatory, clinical and R&D departments. Thompson also led the April 2021 acquisition and subsequent integration of PQ Bypass. He is a contract staff surgeon in the Department of Vascular Surgery, Heart, Vascular and Thoracic Institute at the Cleveland Clinic Foundation Ohio and visiting professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, USA. Previously he was the professor of vascular surgery at St George’s, University of London and a consultant vascular Surgeon at St George’s Vascular Institute in London, UK.
“I have had the pleasure of working side by side with Matt over the past year and have the utmost confidence in his ability to lead Endologix through this transformative period. Matt embodies the fusion of the entrepreneurial vision and subject matter expertise that we need to successfully accelerate Endologix as a leader in the development and commercialisation of the most innovative devices for the treatment of vascular disease,” said Mott.
“I have been extremely impressed with Matt’s leadership of major company initiatives, including the PQ Bypass acquisition and integration, and the AFX FDA [US Food and Drug Administration] advisory panel meeting, as well as his leadership of major functions within the company,” noted Andrew El Bardissi, Deerfield partner and member of the Endologix board of directors. “I am confident in Matt’s ability to step into the CEO role and guide the company during this important period of growth.”
“I am excited about the opportunity to lead such a dynamic and innovative organisation. I look forward to continuing my close relationship with Rich, the board, and the talented and dedicated team of employees that I have worked so closely with over the past several years,” said Thompson. “I will be completely committed to our physician customers and to the safety and health of their patients, as we continue to work collaboratively with the FDA and other global regulatory agencies to ensure we maintain the highest standards possible. In the next year, we will continue to drive market share gains with our family of AAA [abdominal aortic aneurysm] products and prepare our regulatory submissions for our innovative long-lesion PAD [peripheral arterial disease] products being developed after our acquisition of PQ Bypass earlier this year.”
